MediPost saw the highest growth of 0.99% in patent filings and no patents were granted in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of MediPost’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
MediPost has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 100% of filings. The Australia(AU) patent Office are among the top ten patent offices where MediPost is filings its patents..
Mesoblast and Stanford University could be the strongest competitors for MediPost
Patents related to cell & gene therapy lead MediPost's portfolio
MediPost has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Inflammation related patents lead MediPost portfolio followed by fibrosis, and lung disease
MediPost has highest number of patents in inflammation followed by fibrosis, lung disease.
For comprehensive analysis of MediPost's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
